Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Anxiety
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Anxiety
    TopAbstracts in Anxiety 06/25/2008 - (DGNews)
    Pregabalin Effective for Fibromyalgia Pain Regardless of Patient Anxiety or Depression: Presented at EULAR - (DGDispatch)
    TopAbstracts in Anxiety 06/11/2008 - (DGNews)
    TopAbstracts in Anxiety 05/28/2008 - (DGNews)
    TopAbstracts in Anxiety 05/14/2008 - (DGNews)

    News archive

     Recent webcasts/CME - Anxiety
    • Understanding and Managing the Fibromyalgia Syndrome
    • Accurate Diagnosis of Fibromyalgia Is Essential for Effective Management
    • Functional Neuroimaging Studies Illuminate Mechanisms Underlying Development of Fibromyalgia
    • Pharmacologic and Behavioral Approaches Expand Treatment Options for Fibromyalgia
    • Prevalence and Associated Factors for Suicidal Ideation and Behaviors in Obsessive-Compulsive Disorder

      Webcasts/CME archive

       Recent cases - Anxiety
        Recurrence of Suicidal Ideation Due to Treatment with Antidepressants in Anxiety Disorder: A Case Report
        Persistent Tardive Rebound Panic Disorder, Rebound Anxiety and Insomnia Following Paroxetine Withdrawal: a Review of Rebound-Withdrawal Phenomena
        Olfactory Reference Syndrome: Diagnostic Criteria and Differential Diagnosis
        Comedication with Sertraline and Phenprocoumon in Two Patients with Anxiety Disorders
        Self-Hypnosis for Anxiety Associated with Severe Asthma: A Case Report

        Cases archive
          




        my personal edition > anxiety > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Treatment with Serotonin-Norepinephrine Reuptake Inhibitor Reduces Rate of Relapse in Panic Disorder: Presented at CPA

        By Steve Pridgeon

        VANCOUVER, CANADA -- November 10, 2005 -- Research presented at the 55th annual conference of the Canadian Psychiatric Association (CPA) indicates that venlafaxine XR (Effexor XR) maintains its effectiveness during long-term therapy for panic disorder (PD), significantly reducing the risk of relapse.

        Panic disorder is a chronic illness often associated with comorbid psychiatric conditions, including depression and social anxiety disorder. Short-term treatment with the serotonin norepinephrine reuptake inhibitor (SNRI) venlafaxine XR has been shown to be effective, said investigator James Ferguson MD, Clinical Professor of Psychiatry, University of Utah School of Medicine, Salt Lake City, Utah, United States.

        Dr. Ferguson and colleagues conducted a prospective, randomised, double-blind, placebo-controlled study to investigate the ability of venlafaxine XR to prevent relapse in patients who had experienced improvements in PD symptoms with short-term therapy with venlafaxine XR.

        Patients were aged 18 years or older and had a Diagnostic Statistical Manual - Revision IV diagnosis of PD for 3 months or more. They were required to have a Clinical Global Impression - Improvement (CGI-I) score of 4 or greater.

        After 12 weeks of open-label therapy, patients who responded to venlafaxine XR were randomized to venlafaxine XR or placebo for 26 weeks. A response was defined as one or more full-symptom panic attacks per week during the last 2 weeks of open-label treatment and a CGI-I score of 1 or 2.

        Of 291 patients in the open-label phase, 169 were assigned randomly to either venlafaxine XR or placebo in the double-blind phase.

        Time to relapse, which was the primary endpoint of the study, was significantly longer in the treated group than in the placebo group. Kaplan-Meier survival analysis found that 22.5% of patients on venlafaxine XR relapsed, compared to 50% of those in the placebo group (P < .001).

        Patients on venlafaxine XR were less likely to discontinue the study than those on placebo, noted Dr. Ferguson, who concluded that venlafaxine is safe, well tolerated and effective in the long-term treatment and prevention of relapse in patients with PD.

        This presentation was funded by Wyeth Research.


        [Presentation title: Prevention of Panic Disorder Relapse in Adult Outpatient Responders to venlafaxine XR. Abstract P-22]



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send